bioAffinity Technologies Inc

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity publishes peer-reviewed results in PLOS ONE for evaluating lung health by using high-throughput flow cytometry to analyze sputum.

bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE

JERSEY CITY, N.J. , Sept. 6, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today bioAffinity Technologies, Inc. ("bioAffinity" or the "Company") (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, has completed its previously announced initial public offering ("IPO") of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share, for aggregate gross proceeds of approximately $7.8 million, prior to deducting underwriting discounts, commissions, and other offering expenses.

WallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public Offering

SAN ANTONIO--(BUSINESS WIRE)-- #IPO--Cancer diagnostic company bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), announces closing of $7.8 million IPO.

bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering

Source: CI Photos / Shutterstock.com BioAffinity Technologies (NASDAQ: BIAF ) stock is ramping up on Friday as investors push shares higher following its IPO yesterday. That comes as several IPOs have been targeted by traders to pump them higher.

BIAF Stock Alert: 13 Things to Know Following bioAffinity's Red-Hot Debut

Well, it turns out the initial public offering ( IPO ) market isn't quite dead. The latest IPO to hit the markets today is that of bioAffinity (NASDAQ: BIAF ).

bioAffinity (BIAF) Stock Pops 100% in Red-Hot IPO

News for bioAffinity Technologies Inc Stock (BIAF)